Genuine DNA/polyethylenimine (PEI) Complexes Improve Transfection Properties and Cell Survival
Overview
Authors
Affiliations
Polyethylenimine (PEI) has been described as one of the most efficient cationic polymers for in vitro gene delivery. Systemic delivery of PEI/DNA polyplexes leads to a lung-expression tropism. Selective in vivo gene transfer would require targeting and stealth particles. Here, we describe two strategies for chemically coupling polyethylene glycol (PEG) to PEI, to form protected ligand-bearing particles. Pre-grafted PEG-PEI polymers lost their DNA condensing property, hence their poor performances. Coupling PEG to pre-formed PEI/DNA particles led to the expected physical properties. However, low transfection efficacies raised the question of the fate of excess free polymer in solution. We have developed a straightforward a purification assay, which uses centrifugation-based ultrafiltration. Crude polyplexes were purified, with up to 60% of the initial PEI dose being removed. The resulting purified and unshielded PEI/DNA polyplexes are more efficient for transfection and less toxic to cells in culture than the crude ones. Moreover, the in vivo toxicity of the polyplexes was greatly reduced, without affecting their efficacy.
Taghizadeh-Tabarsi R, Akbari-Birgani S, Amjadi M, Mohammadi S, Nikfarjam N, Kusamori K Sci Rep. 2024; 14(1):24104.
PMID: 39406784 PMC: 11480468. DOI: 10.1038/s41598-024-74312-9.
Dash S, Sharon D, Mullick A, Kamen A Biotechnol Bioeng. 2022; 119(6):1685-1690.
PMID: 35182435 PMC: 9314941. DOI: 10.1002/bit.28068.
Llorens M, Rossi F, Garcia I, Cooke M, Abba M, Lopez-Haber C Front Oncol. 2019; 9:1323.
PMID: 31828042 PMC: 6890807. DOI: 10.3389/fonc.2019.01323.
Bioreducible Poly(Amino Ethers) Based mTOR siRNA Delivery for Lung Cancer.
Gandhi N, Godeshala S, Koomoa-Lange D, Miryala B, Rege K, Chougule M Pharm Res. 2018; 35(10):188.
PMID: 30105526 PMC: 8463011. DOI: 10.1007/s11095-018-2460-z.
Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma.
Hobel S, Appeldoorn C, Gaillard P, Aigner A Pharmaceuticals (Basel). 2016; 4(12):1591-1606.
PMID: 27721338 PMC: 4060103. DOI: 10.3390/ph4121591.